nach oben

International Urology and Nephrology

Erschienen in:

10.06.2024 | Nephrology – Review

Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting

verfasst von: Marco Simonini, Arianna Bologna, Giuseppe Vezzoli

Erschienen in: International Urology and Nephrology | Ausgabe 10/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In patients with chronic kidney disease (CKD), renal osteodystrophy may be associated with a progressive bone mass loss that increases fracture risk. Denosumab, a monoclonal antibody inhibiting osteoclast activity, is an antiresorptive medication used for the treatment osteoporosis.

Methods

Its efficacy and safety were initially established in the FREEDOM study, showing a significant reduction in incident fractures in osteoporotic women treated with denosumab. Subsequent post hoc analyses showed its efficacy in patients stratified by kidney function, but these analyses did not include patients with advanced stages of CKD. The capability of denosumab in improving bone mineral density in uremic patients was evaluated in 12 studies including 461 dialysis patients with low bone mineral density. The improvement of bone mineral density was the final end point in these studies assessed during a follow-up of 6–60 months. Nine of these studies did not have hyperparathyroidism among criteria for patient inclusion and their participants may have low-turnover bone disease. Despite current recommendations, no patients underwent bone biopsy before denosumab therapy.

Results

Overall, findings in these studies suggest that denosumab is a viable option for promoting bone mass recovery in patients with advanced stages of CKD having either high or low serum levels of PTH. However, the increase of bone mineral density was lower in patients with low serum markers of bone turnover at baseline. These studies also highlighted the need for calcium and vitamin D supplementation to prevent hypocalcemia that remains a serious concern.

Conclusions

Denosumab emerges as a potentially safe and effective option for enhancing bone health in CKD patients.

Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818. https://doi.org/10.1038/ki.2013.547CrossRefPubMed

Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y et al (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Min Metab 31:315–321. https://doi.org/10.1007/s00774-012-0411-zCrossRef

Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E et al (2020) Risks of hip and nonvertebral fractures in patients with CKD G3a–G5D: A systematic review and meta-analysis. Am J Kidney Dis 76:521–532. https://doi.org/10.1053/j.ajkd.2020.02.450CrossRefPubMed

Arneson TJ, Li S, Liu J, Kilpatrick RD, Newsome BB, St. Peter WL, (2013) Trends in hip fracture rates in US hemodialysis patients, 1993–2010. Am J Kidney Dis 62:747–754. https://doi.org/10.1053/j.ajkd.2013.02.368CrossRefPubMed

Hansen D, Olesen JB, Gislason GH, Abrahamsen B, Hommel K (2016) Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. Nephrol Dial Transplant 31:1654–1662. https://doi.org/10.1093/ndt/gfw073CrossRefPubMed

Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H et al (2013) p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56:347–354. https://doi.org/10.1016/j.bone.2013.07.002CrossRefPubMed

Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M et al (2007) Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71:738–743. https://doi.org/10.1038/sj.ki.5002097CrossRefPubMed

Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G et al (2017) Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio 7:1178–1185. https://doi.org/10.1002/2211-5463.12258CrossRefPubMedPubMedCentral

Iwasaki Y, Kazama JJ, Yamato H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477–483. https://doi.org/10.1016/j.bone.2013.07.037CrossRefPubMed

10.

Drueke T, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89:289–302. https://doi.org/10.1016/j.kint.2015.12.004CrossRefPubMed

11.

Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre G et al (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:160–166. https://doi.org/10.1038/ki.1994.380CrossRef

12.

Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3:446–450. https://doi.org/10.1038/kisup.2013.93CrossRef

13.

Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease–mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78:582–589. https://doi.org/10.1053/j.ajkd.2020.12.024CrossRefPubMed

14.

Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ et al (2010) Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21:1371–1380. https://doi.org/10.1681/ASN.2009121208CrossRefPubMedPubMedCentral

15.

Nickolas TL, Stein E, Dworakowski E, Nishiyama KK, Mafo Komandah-Kosseh M, Zhang CA et al (2013) Rapid cortical bone loss in patients with chronic kidney disease. J Bone Min Res 28:1811–1820. https://doi.org/10.1002/jbmr.1916CrossRef

16.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130. https://doi.org/10.1038/ki.2009.188CrossRef

17.

Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67:559–566. https://doi.org/10.1053/j.ajkd.2015.06.023CrossRefPubMed

18.

Fusaro M, Cianciolo G, Tripepi G, Plebani M, Aghi A, Politi C et al (2021) Oral calcitriol use, vertebral fractures, and vitamin K in hemodialysis patients: A cross-sectional study. J Bone Min Res 36:2361–2370. https://doi.org/10.1002/jbmr.4440CrossRef

19.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420. https://doi.org/10.1056/NEJMoa1305224CrossRefPubMed

20.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meiser PD, Miller PD et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183–3193. https://doi.org/10.1210/jc.2017-02163CrossRefPubMed

21.

Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I et al (2010) Effects of denosumab on bone histomorphometry: The FREEDOM and STAND Studies. J Bone Min Research 25:2256–2265. https://doi.org/10.1002/jbmr.149CrossRef

22.

Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Beck Jensen JE et al (2014) Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Min Research 29:2051–2056. https://doi.org/10.1002/jbmr.2236CrossRef

23.

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523. https://doi.org/10.1016/S2213-8587(17)30138-9CrossRefPubMed

24.

Damasiewicz MJ, Nickolas TL (2018) Rethinking bone disease in kidney disease. JBMR Plus 2:309–322. https://doi.org/10.1002/jbm4.10117CrossRefPubMedPubMedCentral

25.

Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13:962–969. https://doi.org/10.2215/CJN.11031017CrossRefPubMedPubMedCentral

26.

Ginsberg C, Ix JH (2022) Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis 79:427–436. https://doi.org/10.1053/j.ajkd.2021.06.031CrossRefPubMed

27.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. https://doi.org/10.1056/NEJMoa0809493CrossRefPubMed

28.

Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835. https://doi.org/10.1002/jbmr.403CrossRefPubMed

29.

Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397–409. https://doi.org/10.1210/clinem/dgaa851CrossRefPubMed

30.

Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479. https://doi.org/10.1002/jbmr.1613CrossRefPubMed

31.

Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC et al (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426–2432. https://doi.org/10.1210/jc.2014-1154CrossRefPubMed

32.

Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC et al (2015) Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab 100:2784–2792. https://doi.org/10.1210/jc.2015-1259CrossRefPubMed

33.

Chen CL, Chen NC, Wu FZ, Wu MT (2020) Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int 31:1507–1516. https://doi.org/10.1007/s00198-020-05391-3CrossRefPubMed

34.

Takami H, Washio K, Gotoh H (2017) Denosumab for male hemodialysis patients with low bone mineral density: a case-control study. Int J Nephrol 2017:6218129. https://doi.org/10.1155/2017/6218129CrossRefPubMedPubMedCentral

35.

Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, Yamamoto Y et al (2019) Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res 34:1014–1024. https://doi.org/10.1002/jbmr.3676CrossRefPubMed

36.

Kunizawa K, Hiramatsu R, Hoshino J, Mizuno H, Ozawa Y, Sekine A et al (2020) Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep 10:2496. https://doi.org/10.1038/s41598-020-59143-8CrossRefPubMedPubMedCentral

37.

Hiramatsu R, Ubara Y, Sawa N, Sakai A (2021) Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant 36:1900–1907. https://doi.org/10.1093/ndt/gfaa359CrossRefPubMed

38.

Hori M, Yasuda K, Takahashi H, Kondo C, Shirasawa Y, Ishimaru Y et al (2022) Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients. Sci Rep 12:7781. https://doi.org/10.1038/s41598-022-12029-3CrossRefPubMedPubMedCentral

39.

Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S et al (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30:271–279. https://doi.org/10.1007/s40620-016-0334-1CrossRefPubMed

40.

Han SH, Jo HA, Han KH, Han SY (2022) Lower response to denosumab in diabetes patients on hemodialysis. Clin Nephrol 97:70–77. https://doi.org/10.5414/CN110473CrossRefPubMed

41.

Kim H, Lee EJ, Woo S, Rho S, Jung JY (2024) Effect of denosumab on bone health, vascular calcification, and health-related quality of life in hemodialysis patients with osteoporosis: a prospective observational study. J Clin Med 13:1462. https://doi.org/10.3390/jcm13051462CrossRefPubMedPubMedCentral

42.

Iseri K, Mizobuchi M, Winzenrieth R, Humbert L, Saitou T, Kato T et al (2023) Long-term effect of denosumab on bone disease in patients with CKD. Clin J Am Soc Nephrol 18:1195–1203. https://doi.org/10.2215/CJN.0000000000000213CrossRefPubMedPubMedCentral

43.

Yokoyama K, Taniguchi M, Fukagawa M (2013) A japanese approach for CKD-MBD. Kidney Int Suppl 3:451–456. https://doi.org/10.1038/kisup.2013.94CrossRef

44.

Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant 36:42–59. https://doi.org/10.1093/ndt/gfaa192CrossRefPubMed

45.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB et al (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280–1289. https://doi.org/10.1002/jbmr.2480CrossRefPubMed

46.

Papapoulos S, Lippuner K, Roux LCJF, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783. https://doi.org/10.1007/s00198-015-3234-7CrossRefPubMedPubMedCentral

47.

Cummings SR, Ferrari S, Eastell R, Gilchrist N, Beck Jensen JE, McClung M et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-Controlled FREEDOM trial and its extension. J Bone Miner Res 33:190–198. https://doi.org/10.1002/jbmr.3337CrossRefPubMed

48.

Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R et al (2024) Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331:491–499 https://doi.org/10.1001/jama.2023.28239CrossRefPubMedPubMedCentral

Titel: Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting
verfasst von: Marco Simonini
Arianna Bologna
Giuseppe Vezzoli
Publikationsdatum: 10.06.2024
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 10/2024
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-024-04110-9

Serum IgA/C3 ratio: a useful marker of disease activity in patients with IgA nephropathy

Nephrology - Original Paper

Nephron-sparing surgery in metastatic renal cell carcinoma

Urology – Letter to the Editor

Burden levels and predictive factors among caregivers of hemodialysis patients: a cross-sectional study in Oman

Nephrology – Original Paper

The heart rate non-dipping pattern was associated with target organ damage in patients with chronic kidney disease

Nephrology – Original Paper

Chronic kidney disease, an expanding plague: time to wake up!

Editorial

Tubulointerstitial injury and renal outcome after minimum lethal dose of diquat intoxication

Nephrology – Letter to the Editor

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schützt das tägliche Glas Milch vor Darmkrebs?

17.01.2025
Kolorektales Karzinom
Nachrichten

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting